Unicycive Therapeutics Inc (UNCY) Live Share Price, Invest From India

Unicycive Therapeutics Inc Stock Performance

as on April 28, 2026 at 6:59 am IST

Day's Low
Day's High
$7.18
Day's Price Range
$7.65
$7.22
0.55%
Downside
5.96%
Upside
52 Week's Low
52 Week's High
$3.71
52-Week Price Range
$11.00
$7.22
48.61%
Downside
52.35%
Upside

Unicycive Therapeutics Inc share price movements today

Previous Close: $7.29
Open: $7.35
Volume: 684.9K
Day's Low - High: $7.18 - $7.65
52 Week Low - High: $3.71 - $11.00

Unicycive Therapeutics Inc Historical Returns

1 Month Return: + 14.08 %
3 Month Return: + 1.25 %
1 Year Return: + 13.91 %
3 Year Return: -45.19 %
5 Year Return: 0 %

Unicycive Therapeutics Inc Stock Fundamentals & Key Indicators

Check Unicycive Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$184.0M

EPS (TTM)

0.7113

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-29.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-141.15%

Unicycive Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Unicycive Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Unicycive Therapeutics Inc	BUY	$184.0M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.8B	116.23%	131.7	8.45%
Vertex Pharmaceuticals Inc	BUY	$109.5B	99.64%	28.1	32.94%
BeiGene, Ltd.	NA	$33.4B	NA	121.78	5.37%
Regeneron Pharmaceuticals Inc	BUY	$79.5B	52.82%	18.11	31.41%

Stock Returns calculator for Unicycive Therapeutics Inc Stock including INR - Dollar returns

The Unicycive Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Unicycive Therapeutics Inc investment value today

Current value as on today

₹1,24,771

Returns

₹24,771

(+24.77%)

Returns from Unicycive Therapeutics Inc Stock

₹12,812 (+12.81%)

Dollar Impact

₹11,958 (+11.96%)

Analyst Recommendation on Unicycive Therapeutics Inc Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Unicycive Therapeutics Inc. Average target price of $39.89

Unicycive Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Unicycive Therapeutics Inc.

What analysts predicted

81.9%UPSIDE

Target Price

$39.89

Current Price

$7.22

Analyzed by

11 Analysts

Target

$39.89

Unicycive Therapeutics Inc target price $39.89, a slight upside of 81.9% compared to current price of $7.22. According to 11 analysts rating.

Unicycive Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Unicycive Therapeutics Inc Stock has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Time period: March 29, 2026 to April 28, 2026

Change:35% versus previous 30 day period

Unicycive Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	0	-	-	-	0	-	-	-	-
Gross Profit	0	0	0	-	0	0	0	0	-	0
Operating Income	-5	-6	-9	-7	-6	-9	-7	-6	-7	-7
EBITDA	-4	-6	-20	-7	-3	-9	0	-6	-5	-14
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-4	-7	-20	9	-4	-21	0	-6	-6	-14
Income Tax Expense	0	-10	0	5	-	0	-	-	-	-
Net Income	-4	-7	-20	9	-4	-21	0	-6	-6	-14
Net Profit Margin	0.00%	2877.49%	0.00%	0.00%	0.00%	-3789.61%	0.00%	0.00%	0.00%	0.00%

Unicycive Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	0	0	-	-
Gross Profit	-	-	0	0	0	0	0
Operating Income	-1	-2	-8	-18	-20	-32	-29
EBITDA	-2	-2	-8	-17	-30	-36	-25
Interest Expense	0	0	0	0	0	0	0
Depreciation	-	-	0	0	0	0	0
Income Before Tax	-2	-2	-10	-18	-30	-36	-26
Income Tax Expense	0	0	0	0	0	-1	-
Net Income	-2	-2	-10	-18	-30	-36	-26
Net Profit Margin	0.00%	0.00%	0.00%	-1899.47%	-4525.04%	0.00%	0.00%

Unicycive Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-7	-20	9	-4	-21	0	-6	-6	-14
Operating Cash Flow	-4	-6	-6	-9	-6	-8	-8	-5	-8
Investing Cash Flow	-	0	0	0	0	0	0	0	-12
Financing Cash Flow	0	45	0	0	0	2	10	26	6
Change in Cash	-4	39	-7	-9	-6	-6	2	20	-13

Unicycive Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-2	-2	-10	-18	-30	-36	-26
Operating Cash Flow	-1	-1	-5	-15	-18	-28	-31
Investing Cash Flow	0	0	0	0	0	0	-12
Financing Cash Flow	1	1	22	0	27	45	46
Change in Cash	0	0	16	-16	9	16	3

Global Institutional Holdings in Unicycive Therapeutics Inc

Funds	Holdings
Geode Capital Management, LLC	0.68%
Omers Administration Corp	0.31%
XTX Topco Ltd	0.14%
State Street Corp	0.22%
Renaissance Technologies Corp	0.07%

See all

Insights on Unicycive Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, -271.0K → 568.0K (in $), with an average increase of 147.7% per quarter
POSITIVE IMPACT
Price Rise
In the last 6 months, UNCY stock has moved up by 39.1%
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 24.7% return, outperforming this stock by 10.8%
NO EFFECT
Against Peers
In the last 3 years, Unicycive Therapeutics Inc has experienced a drawdown of -45.2%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 40.1%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -6.01M → -14.66M (in $), with an average decrease of 144.0% per quarter

About Unicycive Therapeutics Inc

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

Organisation	Unicycive Therapeutics Inc
Headquarters	4300 El Camino Real, Los Altos, CA, United States, 94022
Industry	Biotechnology
CEO	Dr. Shalabh K. Gupta M.D., MPA
E-voting on shares	Click here to vote

Key Management of Unicycive Therapeutics Inc

Name	Title
Mr. Douglas Jermasek M.B.A.	Executive Vice President of Corporate Strategy
Mr. John W. Townsend CPA	Chief Financial Officer
Dr. Shalabh K. Gupta M.D., MPA	Founder, Chairman, CEO & President
Dr. Pramod Gupta Ph.D.	Executive Vice President of Operations

FAQs

What is Unicycive Therapeutics Inc share price today?

Unicycive Therapeutics Inc share price today is $7.22 as on April 28, 2026 at 1:29 am IST at the close of the market. Unicycive Therapeutics Inc share today touched a day high of $7.65 and a low of $7.18.

What is the 52 week high and 52 week low for Unicycive Therapeutics Inc share?

Unicycive Therapeutics Inc share touched a 52 week high of $11 on June 9, 2025 and a 52 week low of $3.71 on September 25, 2025. Unicycive Therapeutics Inc stock price today i.e. April 28, 2026 at 1:29 am IST is closed at $7.22,which is 34.36% down from its 52 week high and 94.61% up from its 52 week low.

What is Unicycive Therapeutics Inc's market capitalisation today?

Unicycive Therapeutics Inc market capitalisation is $0.00T as on April 28, 2026 at 1:29 am IST.

How to invest in Unicycive Therapeutics Inc Stock (UNCY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Unicycive Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Unicycive Therapeutics Inc Shares that will get you 0.2078 shares as per Unicycive Therapeutics Inc share price of $7.22 per share as on April 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Unicycive Therapeutics Inc Stock (UNCY) from India?

Indian investors can start investing in Unicycive Therapeutics Inc (UNCY) shares with as little as ₹94.19 or $1 (as of April 28, 2026 at 4:41 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹941.90 in Unicycive Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on April 28, 2026 at 4:41 am IST). Based on Unicycive Therapeutics Inc share’s latest price of $7.22 as on April 28, 2026 at 1:29 am IST, you will get 1.3850 shares of Unicycive Therapeutics Inc. Learn more about fractional shares .